Tin Etiopurpurin

  • Photosensitizer: Tin Etiopurpurin
  • Tradename: Purlytin™
  • Company Photosensitizer: Miravant Medica Technologies
  • Clinical Application: Macular degeneration, metastatic breast cancer, Kaposi’s sarcoma, prostatic cancer, brain, lung, skin and head and neck cancer, psoriasis, restenois
  • Wavelength (nm): 660
  • Extinction Coefficient (M-1 cm-1): 2.8 104
  • Mode of Delivery: Intravenous
  • Delivery vehicle: Lipid emulsion
  • Typical Dose (mg kg-1): 1.0–2.0
  • Light Dose (J cm-2): 100–200
  • Time Post-Injection: 24 h
  • Duration of Skin Photosensitivity: Up to 1 month

Miravant Medical Technologies (Santa Barbara, CA, USA) markets tin etiopurpurin (SnET2)[85] as Puryltin™ as part of their PhotoPoint™ procedure. The PhotoPoint procedure involves three components: a light-activated photosensitizer, a light-producing device and a light-delivery system and is described in details on their Internet site (http://www.miravant.com).

Puryltin is among the most developed of Miravant’s light-activated compounds, and is currently in Phase III clinical trials for the treatment of wet AMD (in collaboration with Pharmacia & Upjohn, Bridgewater, NJ, USA). The photosensitizer is also in Phase I clinical trials against prostatic cancer (that has not spread beyond the prostate itself) and in Phase II trials for cutaneous metastatic breast cancer and Kaposi’s sarcoma in patients with acquired immunodeficiency syndrome (AIDS).

Preclinical work with SnET2 has included extensive examination of its effects on other malignancies such as brain, lung, skin, head and neck cancer. Non-malignant conditions such as psoriasis and restenosis are also effectively treated using SnET2.

Tin Etiopurpurin